- Home
- NMRA vs OCGN Comparison
NMRA vs OCGN Comparison
Compare NMRA & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- OCGN
- Stock Information
- Founded
- NMRA 2019
- OCGN 2013
- Country
- NMRA United States
- OCGN United States
- Employees
- NMRA N/A
- OCGN N/A
- Industry
- NMRA
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMRA
- OCGN Health Care
- Exchange
- NMRA Nasdaq
- OCGN Nasdaq
- Market Cap
- NMRA 291.5M
- OCGN 321.7M
- IPO Year
- NMRA 2023
- OCGN N/A
- Fundamental
- Price
- NMRA $2.50
- OCGN $1.50
- Analyst Decision
- NMRA Buy
- OCGN Strong Buy
- Analyst Count
- NMRA 8
- OCGN 2
- Target Price
- NMRA $7.43
- OCGN $7.00
- AVG Volume (30 Days)
- NMRA 2.3M
- OCGN 5.9M
- Earning Date
- NMRA 11-06-2025
- OCGN 11-05-2025
- Dividend Yield
- NMRA N/A
- OCGN N/A
- EPS Growth
- NMRA N/A
- OCGN N/A
- EPS
- NMRA N/A
- OCGN N/A
- Revenue
- NMRA N/A
- OCGN $4,754,000.00
- Revenue This Year
- NMRA N/A
- OCGN N/A
- Revenue Next Year
- NMRA N/A
- OCGN N/A
- P/E Ratio
- NMRA N/A
- OCGN N/A
- Revenue Growth
- NMRA N/A
- OCGN N/A
- 52 Week Low
- NMRA $0.61
- OCGN $0.52
- 52 Week High
- NMRA $14.09
- OCGN $1.90
- Technical
- Relative Strength Index (RSI)
- NMRA 68.71
- OCGN 48.14
- Support Level
- NMRA $1.68
- OCGN $1.47
- Resistance Level
- NMRA $2.72
- OCGN $1.65
- Average True Range (ATR)
- NMRA 0.20
- OCGN 0.11
- MACD
- NMRA 0.08
- OCGN -0.03
- Stochastic Oscillator
- NMRA 81.89
- OCGN 13.51
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").